Tag: M.W=200-350

Banday, Aaqib Zaffar published the artcileRefractory Autoimmune Cytopenia in a Young Boy with a Novel LRBA Mutation Successfully Managed with Sirolimus, SDS of cas: 55981-09-4, the main research area is autoimmune cytopenia LRBA mutation sirolimus.

In this article the author is discussing about refractory autoimmune cytopenia in a young boy with a novel LRBA mutation successfully managed with sirolimus. A 9-yr-old boy presented with history of recurrent diar-rhea and anemia requiring multiple blood transfusions. On examination, he had pallor, hepatosplenomegaly, severe wasting, and stunting. Replacement i.v. Ig (IVIg) therapy (400 mg/kg/mo) and cotrimoxazole prophylaxis (5 mg/kg/day of the trimethoprim component) were initiated along with iron, folic acid, and vitamin B12 supplementation. He showed some clin. improvement in diarrhea and anemia. After 6 mo of follow-up, he had to be initiatedonoral prednisolone(1mg/kg/day)in view of falling Hb and DCT positivity (both IgG and C3d). A clin. possibility of monogenic CVID with autoimmune cytopenia and benign lymphoproliferation was considered and targeted next generation sequencing was carried out. He has been taking sirolimus for past 9 mo now,and no blood transfusions were given after initiation of sirolimus. Index patient showed a transient response to oral cortico-steroids and IVIg.

Journal of Clinical Immunology published new progress about Anemia. 55981-09-4 belongs to class esters-buliding-blocks, name is 2-((5-Nitrothiazol-2-yl)carbamoyl)phenyl acetate, and the molecular formula is C12H9N3O5S, SDS of cas: 55981-09-4.

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

Ranjbar, Shahin published the artcileCytoplasmic RNA Sensor Pathways and Nitazoxanide Broadly Inhibit Intracellular Mycobacterium tuberculosis Growth, Related Products of esters-buliding-blocks, the main research area is cytoplasm RNA sensor signaling nitazoxanide Mycobacterium infection growth; Biological Sciences; Immune Response; Immunology; Microbiology; Molecular Microbiology.

To establish stable infection, Mycobacterium tuberculosis (MTb) must overcome host innate immune mechanisms, including those that sense pathogen-derived nucleic acids. Here, we show that the host cytosolic RNA sensing mols. RIG-I-like receptor (RLR) signaling proteins RIG-I and MDA5, their common adaptor protein MAVS, and the RNA-dependent kinase PKR each independently inhibit MTb growth in human cells. Furthermore, we show that MTb broadly stimulates RIG-I, MDA5, MAVS, and PKR gene expression and their biol. activities. We also show that the oral FDA-approved drug nitazoxanide (NTZ) significantly inhibits intracellular MTb growth and amplifies MTb-stimulated RNA sensor gene expression and activity. This study establishes prototypic cytoplasmic RNA sensors as innate restriction factors for MTb growth in human cells and it shows that targeting this pathway is a potential host-directed approach to treat tuberculosis disease.

iScience published new progress about Cytosol. 55981-09-4 belongs to class esters-buliding-blocks, name is 2-((5-Nitrothiazol-2-yl)carbamoyl)phenyl acetate, and the molecular formula is C12H9N3O5S, Related Products of esters-buliding-blocks.

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

Kute, Vivek B. published the artcileConsequences of the first and second COVID -19 wave on kidney transplant recipients at a large Indian transplant centre, Application of 2-((5-Nitrothiazol-2-yl)carbamoyl)phenyl acetate, the main research area is coronavirus disease consequence neutrophil kidney transplant human India; COVID-19; first wave; kidney transplant recipients; second wave.

There is a scarcity of data comparing the consequences of first and second COVID-19 waves on kidney transplant recipients (KTRs) in India. We conducted a single-center retrospective study of 259 KTRs with COVID-19 to compare first wave (March 15-Dec. 31 2020, n = 157) and second wave (Apr. 1-May 31 2021, n = 102). KTRs during second wave were younger (43 vs. 40 years; p-value .04) and also included paediatric patients (0 vs. 5.9%; p-value .003). Symptoms were milder during the second wave (45 vs. 62.7%; p-value .007); COVID-19 pos. patients had less frequent cough (32 vs. 13.8%; p-value .001), fever was less frequent (58 vs. 37%; p-value .001), and we observed fewer co-morbidities (11 vs. 20.6%; p-value .04). The percentages of neutrophils (77 vs. 83%; p-value .001) and serum ferritin (439 vs. 688; p-value .0006) were higher during second wave, while lymphocyte counts were reduced (20 vs. 14%; p-value .0001). Hydroxychloroquine (11 vs. 0%; p-value .0001) and tocilizumab (7 vs. 0%; p-value .004) were more frequently prescribed during first wave, while utilization of dexamethasone (6 vs. 27%; p-value .0001) and remdesivir (47 vs. 65%; p-value .03) increased during the second wave. Mucormycosis (1.3 vs. 10%; p-value .01) and ICU admissions (20 vs. 37.2%; p-value .002) were more frequent during second wave. The 28-day mortality rate (9.6 vs. 10%; p-value 1) was not different. There has been a different clin. spectrum of COVID-19 amongst KTR with similar mortality between the two waves at a large Indian transplant center.

Nephrology published new progress about Ageusia. 55981-09-4 belongs to class esters-buliding-blocks, name is 2-((5-Nitrothiazol-2-yl)carbamoyl)phenyl acetate, and the molecular formula is C12H9N3O5S, Application of 2-((5-Nitrothiazol-2-yl)carbamoyl)phenyl acetate.

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

Roshan, Niloufar published the artcileTwo-day enema antibiotic therapy for parasite eradication and resolution of symptoms, Safety of 2-((5-Nitrothiazol-2-yl)carbamoyl)phenyl acetate, the main research area is antibiotic enema Blastocystis Dientamoeba infection; Antibiotics; Blastocystis hominis; Dientamoeba fragilis; Parasitic infection; Rectal enema route; Triple therapy.

Blastocystis hominis (B. hominis) and Dientamoeba fragilis (D. fragilis) are two protozoan parasites of human bowel that are found throughout the world. There is still debate about the pathogenicity of these protozoans, despite them being commonly associated with gastrointestinal symptoms and can cause health issue in both children and adults. These parasites are usually transmitted through faecal-oral contact particularly under poor hygiene conditions or food/water contamination. Once a person is infected, the parasites live in the large intestine and are passed in the faeces. To investigate the effect of triple antibiotic therapy using enema infusion in the treatment of B. hominis and D. fragilis infections. This retrospective longitudinal study was conducted in a single medical center, which included fifty-four patients (> 18 years) who were pos. for D. fragilis, B. hominis or both between 2017 and 2018. The treatment consisted of triple antibiotics that were infused over two consecutive days through rectal enema. Faecal samples were collected from participants pre- and post-treatment and were tested for parasites using microscopy and polymerase chain reaction. Patients’ symptoms were recorded prior and after the treatment as well as patient demog. data. Patients (n = 54), were either pos. for B. hominis (37%), D. fragilis (35%) or both (28%). All patients completed the two-day treatment and no serious adverse effect was reported. The most common side effect experienced by the patients during the treatment was urine discoloration which was cleared by six weeks of follow-up. Common symptoms reported prior to treatment were diarrhoea, abdominal pain, constipation and fatigue. Other symptoms included abdominal discomfort, dizziness and blood in the stool. Eighty-nine percent of patients completed a final stool test post-treatment. At six weeks post-treatment, 79% of patients cleared the parasites from their faeces. Symptoms such as abdominal discomfort, dizziness and blood in the stool decreased significantly at both seven days and six weeks post-treatment (P < 0.040). The enema retention time, bowel preparation, previous antibiotic treatment or previous gastrointestinal problems had no significant effect on parasite eradication. Overall, eradication of parasites and improvement of clin. outcomes were observed in treated patients, showing the efficacy of this combination to eradicate the parasites and provide pos. clin. outcome. World Journal of Gastroenterology published new progress about Abdomen. 55981-09-4 belongs to class esters-buliding-blocks, name is 2-((5-Nitrothiazol-2-yl)carbamoyl)phenyl acetate, and the molecular formula is C12H9N3O5S, Safety of 2-((5-Nitrothiazol-2-yl)carbamoyl)phenyl acetate.

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

Cherrez-Ojeda, Ivan published the artcileThe unusual experience of managing a severe COVID-19 case at home: what can we do and where do we go?, Computed Properties of 55981-09-4, the main research area is covid19 pandemic mental disease; Ambulatory care; COVID-19; Developing countries; South America.

Abstract: Background: The speed and reach of the COVID-19 pandemic has created special scenarios to be considered, such as those in where patients who meet criteria for hospitalization due to moderate/severe disease cannot be hospitalized due to economic constraints and saturation of national health systems. The aim of this report is to present an unusual case of a severe COVID-19 patient managed at home in a developing country, and to discuss some of the available guidelines and potential therapeutic options for this type of cases. Case presentation: A 60-yr-old female seeking medical attention through teleconsultation presents with profound dyspnea, oppressive chest pain, fatigue, episodic hallucinations, and difficulty sleeping, for what she originally sought medical attention at an ER but could not be admitted due to saturation of the health system. A pos. PCR test for COVID-19, and a CT scan of the chest showing bilateral consolidations with ground-glass opacities confirmed the diagnosis. The patient was managed at home, with corticosteroids, nitazoxanide and a single dose of 40 mg of s.c. enoxaparin. Colchicine was added at the third day of treatment. Standard oxygen therapy through nasal cannula was also recommended. Daily follow-ups were established to monitor for signs of clin. improvement. Two weeks later from the initial consultation the patient presents marked improvement in her symptoms, as well as in her CT scan, which prompted in discontinuation of the medications and the oxygen therapy. Conclusions: There are several limitations in this report regarding the clin. data and the management, but such limitations do also reflect the state of emergency and the chaos that resides in the health care systems of developing nations. For the ambulatory care of COVID-19 patients, several aspects of disease management may differ from current guidelines and basic requirements may represent a huge challenge to cover. Further research is needed to assist physicians in the daily clin. decision making, to optimize patient outcomes, and to reduce the probability of adverse scenarios of patients with COVID-19 managed in the ambulatory setting.

BMC Infectious Diseases published new progress about COVID-19. 55981-09-4 belongs to class esters-buliding-blocks, name is 2-((5-Nitrothiazol-2-yl)carbamoyl)phenyl acetate, and the molecular formula is C12H9N3O5S, Computed Properties of 55981-09-4.

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

Hemmati, Farshad published the artcileMysterious Virus: A Review on Behavior and Treatment Approaches of the Novel Coronavirus, 2019-nCoV, Safety of 2-((5-Nitrothiazol-2-yl)carbamoyl)phenyl acetate, the main research area is review treatment behavior coronavirus 2019 nCoV; 2019-nCoV; Infection; Novel coronavirus; Respiratory problem; Treatment approach.

At the end of the year 2019, the novel coronavirus (2019-nCoV) was spreading in Wuhan, China, and the outbreak process has a high speed. It was recognized as a pandemic by the World Health Organization (WHO) on 11 March 2020. Coronaviruses are enveloped and single-stranded RNA that have several families including Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS). The pathogenesis mechanism and disease outcomes of SARS and MERS are now clear to some extent, but little information is available for 2019-nCoV. This newly identified corona virus infection represents flu-like symptoms, but usually the first symptoms are fever and dry cough. There has been no specific treatment against 2019-nCoV up to now, and physicians only apply supportive therapy. In the present article, we made an attempt to review the behavior of the virus around the world, epidemiol., a pathway for influx into the host cells, clin. presentation, as well as the treatments currently in use and future approaches; nitazoxanide may be our dream drug. We hope that this review has a pos. impact on public knowledge for helping to deal with the 2019-nCoV and move one step forward toward its treatment in the near future.

Archives of Medical Research published new progress about COVID-19. 55981-09-4 belongs to class esters-buliding-blocks, name is 2-((5-Nitrothiazol-2-yl)carbamoyl)phenyl acetate, and the molecular formula is C12H9N3O5S, Safety of 2-((5-Nitrothiazol-2-yl)carbamoyl)phenyl acetate.

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

Kaddoura, Malak published the artcileCOVID-19 therapeutic options under investigation, Computed Properties of 55981-09-4, the main research area is review human covid19 virus immunomodulator; COVID-19; SARS-CoV-2; adjunctive therapy; antivirals; therapeutics.

Since its emergence in China in Dec. 2019, COVID-19 has quickly spread around the globe causing a pandemic. Vaccination or the development of herd immunity seems the only way to slow down the spread of the virus; however, both are not achievable in the near future. Therefore, effective treatments to mitigate the burden of this pandemic and reduce mortality rates are urgently needed. Preclin. and clin. studies of potential antiviral and immunomodulatory compounds and mols. to identify safe and efficacious therapeutics for COVID-19 are ongoing. Two compounds, remdesivir, and dexamethasone have been so far shown to reduce COVID-19-associated death. Here, we provide a review of the potential therapeutic agents being considered for the treatment and management of COVID-19 patients.

Frontiers in Pharmacology published new progress about COVID-19. 55981-09-4 belongs to class esters-buliding-blocks, name is 2-((5-Nitrothiazol-2-yl)carbamoyl)phenyl acetate, and the molecular formula is C12H9N3O5S, Computed Properties of 55981-09-4.

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

Bishara, Delia published the artcileEmerging and experimental treatments for COVID-19 and drug interactions with psychotropic agents, Category: esters-buliding-blocks, the main research area is human covid19 virus drug interaction psychotropic agent; adverse effects; drug-interactions; psychotropic drugs; treatment COVID-19.

As yet, no agents have been approved for the treatment of COVID-19, although several exptl. drugs are being used off licence. These may have serious adverse effects and potential drug interactions with psychotropic agents. We reviewed the common agents being used across the world for the treatment of COVID-19 and investigated their drug interaction potential with psychotropic agents using several drug interaction databases and resources. A preliminary search identified the following drugs as being used to treat COVID-19 symptoms: atazanavir (ATV), azithromycin (AZI), chloroquine (CLQ)/hydroxychloroquine (HCLQ), dipyridamole, famotidine (FAM), favipiravir, lopinavir/ritonavir (LPV/r), nitazoxanide, remdesivir, ribavirin and tocilizumab. Many serious adverse effects and potential drug interactions with psychotropic agents were identified. The most problematic agents were found to be ATV, AZI, CLQ, HCLQ, FAM and LPV/r in terms of both pharmacokinetic as well as serious pharmacodynamic drug interactions, including QTc prolongation and neutropenia. Significant caution should be exercised if using any of the medications being trialled for the treatment of COVID-19 until robust clin. trial data are available. An even higher threshold of vigilance should be maintained for patients with pre-existing conditions and older adults due to added toxicity and drug interactions, especially with psychotropic agents.

Therapeutic Advances in Psychopharmacology published new progress about COVID-19. 55981-09-4 belongs to class esters-buliding-blocks, name is 2-((5-Nitrothiazol-2-yl)carbamoyl)phenyl acetate, and the molecular formula is C12H9N3O5S, Category: esters-buliding-blocks.

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

Aherfi, Sarah published the artcileDrug repurposing against SARS-CoV-1, SARS-CoV-2 and MERS-CoV, Category: esters-buliding-blocks, the main research area is review COVID 19 drug repurposing SARS health; COVID-19; SARS-CoV-1; SARS-CoV-2; antiviral; coronavirus; drug repurposing; in silico; in vitro testing.

Since the beginning of the COVID-19 pandemic, large in silico screening studies and numerous in vitro studies have assessed the antiviral activity of various drugs on SARS-CoV-2. In the context of health emergency, drug repurposing represents the most relevant strategy because of the reduced time for approval by international medicines agencies, the low cost of development and the well-known toxicity profile of such drugs. Herein, we aim to review drugs with in vitro antiviral activity against SARS-CoV-2, combined with mol. docking data and results from preliminary clin. studies. Finally, when considering all these previous findings, as well as the possibility of oral administration, 11 mols. consisting of nelfinavir, favipiravir, azithromycin, clofoctol, clofazimine, ivermectin, nitazoxanide, amodiaquine, heparin, chloroquine and hydroxychloroquine, show an interesting antiviral activity that could be exploited as possible drug candidates for COVID-19 treatment.

Future Microbiology published new progress about COVID-19. 55981-09-4 belongs to class esters-buliding-blocks, name is 2-((5-Nitrothiazol-2-yl)carbamoyl)phenyl acetate, and the molecular formula is C12H9N3O5S, Category: esters-buliding-blocks.

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

Calderon, Jose Meneses published the artcileNitazoxanide against COVID-19 in three explorative scenarios, Quality Control of 55981-09-4, the main research area is nitazoxanide COVID19 pregnancy; SARS-CoV-2; ambulatory treatment; internal medicine; nitazoxanide; pregnancy.

Introduction: Nitazoxanide has shown efficacy in vitro against coronavirus infections (MERS, SARS, SARS-CoV-2). The aim of this report is to describe the results of treating COVID-19 pos. patients with nitazoxanide in three clin. settings: pregnancy/puerperium, hospitalized patients in an Internal Medicine Service and in an ambulatory setting. Methodol.: This was a prospective follow-up and report of COVID-19 cases in three different situations, pregnant women, hospitalized patients receiving medical attention in an Internal Medicine Service and ambulatory patients residing in Toluca City, and Mexico City. Results: The experience with a first group of 20 women, pregnant (17) or in immediate puerperium (3) was successful in 18 cases with two unfortunate deaths. The five cases treated in an Internal Medicine service showed a pos. outcome with two patients weaned from mech. ventilation. Of the remaining 16 patients treated in an ambulatory setting, all got cured. Nitazoxanide seems to be useful against SARS-CoV-2, not only in an early intervention but also in critical condition as well as in pregnancy without undesired effects for the babies. As an adjunctive therapy budesonide was used that seems to contribute to the clin. improvement. Conclusions: Nitazoxanide could be useful against COVID-19 as a safe and available regimen to be tested in a massive way immediately.

Journal of Infection in Developing Countries published new progress about COVID-19. 55981-09-4 belongs to class esters-buliding-blocks, name is 2-((5-Nitrothiazol-2-yl)carbamoyl)phenyl acetate, and the molecular formula is C12H9N3O5S, Quality Control of 55981-09-4.

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics